Anavex Life Sciences Corp (OTCMKTS:AVXL), a known name in the industry of Biopharma confirmed the appointment of Jacqueline French, MD, to its expert Scientific Advisory Board. She is a known expert with strong hold on epilepsy, clinical trial methodology and unique therapeutic interventions.
The management view
Expressing his views on new appointment, Christopher U. Missling, the CEO and President of Anavex said that the company is excited to have French in its a Scientific Advisory team. The industry knows her as an expert work who has contributed significantly in the segment of epilepsy treatments. The recognition also comes for her contribution in clinical care of seizures. She has extensive experience and expertise in neurology which will be extremely useful Anavex moves forward with development activities of ANAVEX 2-73.
Dr. French played a fundamental part in the sector of development of novel treatments for epilepsy. She co-authored a number of AAN clinical practice plans at the American Academy of Neurology. Also, she carried out the responsibility of bi-annual symposium on trial design. Being an expert in field of neurology, she was included as a key member in the American Academy of Neurology. Dr. French has articulated various research articles, editorials and chapters. The articles have been published in premiere publications. She edited two literatures on epilepsy. The accomplishments do not end at writing as she is also a famous global orator on antiepileptic drug treatments and related topics.
A moment of pride
Talking about the new role with Anavex Dr. French said that she is extremely pleased with the encouraging data for ANAVEX 2-73, which signals a substantial reduction in anti-seizure efficacy. In addition, drug was found to have safety features in Phase 1 human trial. The results of study are vital to support next-general epilepsy therapies. She will work together with Anavex and its team to develop ANAVEX 2-73.